Evaluation of 177Lu|PSMA|617 SPECT/CT Quantitation as a ...

Evaluation of 177 Lu-PSMA-617 SPECT/CT Quantitation ... - PubMed

177 Lu-PSMA-617 is an effective and novel treatment in metastatic castration-resistant prostate cancer (mCRPC). Our ability to assess response rates and ...

Evaluation of 177Lu-PSMA SPECT Quantitation as a Response ...

Results: 32/56 men had analyzable serial 177Lu-SPECT/CT imaging at both C1 and C3. In this subgroup, median PSA-PFS was 6.3 months (95%CI 5-10) ...

Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a ...

Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN) ; DOI. https ...

Evaluation of 177Lu-PSMA SPECT Quantitation as a Response ...

Background: LuPSMA-617 is an effective and novel treatment in metastatic castrate-resistant prostate cancer (mCRPC). Our ability to assess response rates ...

Evaluation of 177 Lu-PSMA SPECT Quantitation as a Response ...

Notably, we could demonstrate this prognostic value at an even earlier therapy stage (6 weeks) with quantitative SPECT/CT without the need for ...

Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a ...

The PSA 50% response rate was 63% (20/32). 177Lu SPECT total tumor volume (SPECT TTV) was reduced in 68% (22/32; median, -0.20 m3 [95% CI, - ...

Assessing the clinical utility of rapid post-therapy whole-body digital ...

Conclusions: Rapid post-therapy whole-body digital SPECT/CT was well tolerated in post-therapy SPECT/CT imaging following 177Lu-PSMA-617 ...

Quantitative imaging for 177Lu-PSMA treatment response ... - Frontiers

SPECT/CT at cycle 1 serves as a baseline scan for RPT, as it is not uncommon to see disease progression between the baseline PSMA PET and the start of the ...

Same-day post-therapy imaging with a new generation whole-body ...

We successfully implemented same-day post-therapy SPECT/CT after [ 177 Lu]Lu-PSMA-617 infusions. Quantitation of 1-2 h post-therapy SPECT/CT ...

Early response monitoring during [177Lu]Lu-PSMA I&T therapy with ...

To assess early tumor response with quantitated SPECT/CT and to correlate it with clinical outcome in metastatic castration–resistant prostate ...

Fast, quantitative SPECT/CT acquisition following multiple therapy ...

This clinical case demonstrates how Symbia Intevo Bold™ with xSPECT Quant™ enables 177Lu-PSMA-617 treatment response assessment.

Assessing the clinical utility of rapid post-therapy whole-body digital ...

therapy whole-body SPECT/CT scan in evaluating early treatment response of 177Lu-PSMA-617 ... quantitative SPECT/CT as a tool for early treatment response.

Evaluation of¹⁷⁷Lu-PSMA-617 SPECT/CT Quantitation ...

Evaluation of¹⁷⁷Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective¹⁷⁷Lu-PSMA-617 and NOX66 Combination Trial ( ...

Comparison of Post-Therapy 4 and 24-hour 177Lu-PSMA SPECT ...

Semi-quantitative total tumor volume, SUVmax, and total body SUVmean were highly correlated between 4- and 24-hour 177Lu-PSMA SPECT/CT with ...

Partial volume correction for Lu-177-PSMA SPECT | EJNMMI Physics

SIMIND Monte Carlo code was used to generate realistic noisy projections. In the clinical study, sequential quantitative SPECT/CT imaging at 4 ...

Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation ... - Altmetric

Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN). · Journal of ...

A multicentre and multi-national evaluation of the accuracy of ...

... quantitative 177Lu SPECT/CT imaging based on a calibration protocol developed and tested in a multicentre inter-comparison. This study ...

Early treatment response assessment with [177Lu]PSMA whole ...

Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT Predicts Overall Survival of MCRPC patients: Subgroup ...

SPECT/CT predicts treatment response in Pluvicto patients

Conversely, Lu-177 PSMA-SPECT/CT has shown promise as a potential response biomarker for therapy, but at an inconvenient 24 hours after patients ...

SPECT/CT in Early Response Assessment of Patients with ...

SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177 Lu-PSMA-617 · No full-text ...